• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

LEO Pharma debuts copay discount

Article

LEO Pharma, the U.S. affiliate of Danish firm LEO Pharma A/S, is offering a copay program for many users of its Taclonex Ointment and Taclonex Scalp Topical Suspension (calcipotriene 0.005 percent, betamethasone dipropionate 0.064 percent) psoriasis medications.

Parsippany, N.J. - LEO Pharma, the U.S. affiliate of Danish firm LEO Pharma A/S, is offering a copay program for many users of its Taclonex Ointment and Taclonex Scalp Topical Suspension (calcipotriene 0.005 percent, betamethasone dipropionate 0.064 percent) psoriasis medications.

According to a LEO statement, the program offers eligible patients copay assistance for a maximum of six prescriptions. The program’s maximum benefit is $200 off per prescription.

Eligible patients for whom either product has been prescribed can obtain a savings card from their provider or by downloading the card at www.taclonex.com. The card can be presented at a pharmacy along with a prescription and is valid until Dec. 31, 2012, when the program expires.

Among the restrictions: The card is invalid for prescriptions reimbursed in whole or part by Medicaid, Medicare or other federal or state programs, or by private indemnity or HMO insurance plans that reimburse the entire cost of prescription drugs. Medicare-eligible patients enrolled in an employer-sponsored health plan or prescription-drug benefit program for retirees also are ineligible, as are those younger than 18.

The program is limited to participating U.S. retail pharmacies and is void in Massachusetts.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.